In today’s episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center in Cleveland, Ohio. He is also a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic. Dr McCloskey is the interim chief of the Division of Leukemia at Hackensack John Theurer Cancer Center in New Jersey. 

In our exclusive interview, Drs Gerds and McCloskey discussed factors that influence their choice between the variety of JAK inhibitors that are FDA approved for patients with myelofibrosis, tips for symptom management in this disease, and emerging myelofibrosis research to look out for.